Stefanie Urlinger

USPTO Granted Patents = 16 (Patent Applications = 1)

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 4.9

ph-index = 3

Forward Citations = 74(Granted Patents)

Location History:

München, DE (2012 - 2013)
Nürnberg, DE (2014 - 2016)
Munich, DE (2013 - 2024)

Company Filing History:

Years Active: 2012-2024

Loading Chart...

16 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12054555 - Anti-BAFFR antibody formulations and methods of use thereof (2024-08-06),

2. 11254734 - Fab molecules with a rodent hinge region and a non-rodent CH1 region (2022-02-22),

3. 10899841 - Anti-BAFFR antibody formulations and methods of use thereof (2021-01-26),

4. 10647757 - Collection and methods for its use (2020-05-12),

5. 9624293 - Collection and methods for its use (2017-04-18),

6. 9541559 - Collection and methods for its use (2017-01-10),

7. 9458240 - Anti-BAFFR antibody formulations (2016-10-04),

8. 9382326 - Compositions and methods of use for therapeutic antibodies (2016-07-05),

9. 9340620 - Compositions and methods of use for therapeutic antibodies (2016-05-17),

10. 9296813 - Compositions and methods of use for antibodies of Dickkopf-1 (2016-03-29),

11. 8728981 - Collection and methods for its use (2014-05-20),

12. 8673306 - Compositions and methods of use for antibodies of dickkopf-1 (2014-03-18),

13. 8388968 - Compositions and methods for increasing muscle growth (2013-03-05),

14. 8367586 - Collection and methods for its use (2013-02-05),

15. 8273688 - Collection of HCDR3 regions and uses therefor (2012-09-25),

Title: The Innovative Journey of Inventor Stefanie Urlinger

Introduction

Stefanie Urlinger, based in Munich, Germany, is an esteemed inventor renowned for her significant contributions to the field of biotechnology. With an impressive portfolio of 16 patents, she has made impactful strides in the development of innovative antibody formulations and applications.

Latest Patents

Among her latest inventions, Urlinger has developed formulations of Anti-BAFFR antibodies, which are available as either lyophilisates or liquid formulations. These innovative formulations can be reconstituted to create solutions that deliver high concentrations of the antibody with minimal aggregation, ensuring effective patient treatment. The lyophilisate can be mixed with an aqueous reconstituent to yield an aqueous composition demonstrating a concentration of at least 50 mg/ml. Additionally, her work includes novel Fab molecules featuring a modified heavy chain constant region that prevents recognition by anti-Fab antibodies in the host serum, broadening the scope for biological, diagnostic, and pharmaceutical applications.

Career Highlights

Urlinger has gained valuable experience in reputable companies throughout her career, including Novartis AG and MorphoSys AG. Her dedication to innovation has been a cornerstone of her professional journey, influencing advancements in therapeutic antibodies.

Collaborations

Throughout her career, Stefanie has collaborated with distinguished professionals, including Julia Neugebauer and Christoph Heusser. These partnerships have facilitated the sharing of ideas and fostered creativity in her research pursuits.

Conclusion

As an accomplished inventor, Stefanie Urlinger continues to advance the field of biotechnology through her innovative work and collaboration. With her extensive patent portfolio, she exemplifies the spirit of innovation that is essential for continued progress in medical science. Her contributions are sure to resonate within the industry for years to come.

This text is generated by artificial intelligence and may not be accurate.